Max Healthcare

  • Market Cap: Large Cap
  • Industry: Hospital
  • ISIN: INE027H01010
  • NSEID: MAXHEALTH
  • BSEID: 543220
INR
948.50
-9.45 (-0.99%)
BSENSE

Jan 29

BSE+NSE Vol: 15.24 lacs

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

15.24 lacs (-6.12%) Volume

Shareholding (Dec 2025)

FII

50.55%

Held by 997 FIIs

DII

2.99%

Held by 109 DIIs

Promoter

23.72%

Is Max Healthcare overvalued or undervalued?

09-Jun-2025

As of October 29, 2021, Max Healthcare Institute Ltd. is considered very expensive with a PE ratio of 100.29, significantly higher than its peers, indicating it may be overvalued despite a 43% return over the past year compared to the Sensex's 7.55%.

As of 29 October 2021, the valuation grade for Max Healthcare Institute Ltd. moved from does not qualify to very expensive, indicating a significant shift in its perceived value. The company is currently overvalued, with a PE Ratio of 100.29, a Price to Book Value of 12.11, and an EV to EBITDA of 62.71. These ratios suggest that the stock is trading at a premium compared to its earnings and book value.<BR><BR>In comparison to its peers, Max Healthcare's valuation appears steep, as it has a higher PE ratio than many competitors in the healthcare sector. For instance, while Max Healthcare's PE stands at 100.29, other industry players typically exhibit lower ratios, indicating that investors may be paying a high price for expected growth that may not materialize. Notably, the company's stock has outperformed the Sensex over the past year, with a return of 43% compared to the Sensex's 7.55%, which may have contributed to the inflated valuation.

View full answer

Who are in the management team of Max Healthcare?

06-Jun-2025

As of March 2023, the management team of Max Healthcare includes Chairman Abhay Soi, along with several non-executive and independent directors: Anil Bhatnagar, K Narasimha Murthy, Mahendra Lodha, Michael Thomas Neeb, Pranav Amin, Amrita Gangotra, and Narayan Seshadri.

As of March 2023, the management team of Max Healthcare includes the following individuals:<BR><BR>1. Abhay Soi - Chairman / Executive Director<BR>2. Anil Bhatnagar - Non-Executive & Non-Independent Director<BR>3. K Narasimha Murthy - Independent Non-Executive Director<BR>4. Mahendra Lodha - Independent Non-Executive Director<BR>5. Michael Thomas Neeb - Independent Non-Executive Director<BR>6. Pranav Amin - Independent Non-Executive Director<BR>7. Amrita Gangotra - Independent Non-Executive Director<BR>8. Narayan Seshadri - Non-Executive Director<BR><BR>These individuals play various roles within the company's governance structure.

View full answer

Has Max Healthcare declared dividend?

06-Jun-2025

Max Healthcare Institute Ltd has declared a 15% dividend, amounting to ₹1.5 per share, with an ex-date of August 23, 2024. The company has shown significant price appreciation over the years, particularly with a total return of 220.75% over three years.

Max Healthcare Institute Ltd has declared a 15% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 15%<BR>- Amount per share: 1.5<BR>- Ex-date: 23 Aug 24<BR><BR>Dividend Yield: 0.13%.<BR><BR>Total Returns by Period:<BR>In the 6-month period, the price return was 6.09%, with a dividend return of 0%, resulting in a total return of 6.09%.<BR><BR>For the 1-year period, the price return was 40.24%, the dividend return was 0.19%, leading to a total return of 40.43%.<BR><BR>Over the 2-year period, the price return was 122.44%, with a dividend return of 0.42%, culminating in a total return of 122.86%.<BR><BR>In the 3-year period, the price return reached 220.06%, while the dividend return was 0.69%, resulting in a total return of 220.75%.<BR><BR>For the 4-year period, the price return was 373.32%, with a dividend return of 0.98%, leading to a total return of 374.3%.<BR><BR>In the 5-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>Overall, Max Healthcare has declared a dividend, which contributes to its total returns, particularly noticeable over longer periods. The company shows strong price appreciation, especially in the 3 to 4-year periods, despite lower dividend contributions.

View full answer

Who are the peers of the Max Healthcare?

03-Jun-2025

Max Healthcare's peers include Apollo Hospitals, Fortis Health, Narayana Hrudaya, Global Health, Aster DM Health, Krishna Institute, Rainbow Child, Dr. Agarwal's Health, and Jupiter Life Line. Among these, Max Healthcare and Apollo Hospitals show excellent growth and management risk, while Krishna Institute has the highest 1-year return at 85.24%.

Peers: Max Healthcare, Apollo Hospitals, Fortis Health., Narayana Hrudaya, Global Health, Aster DM Health., Krishna Institu., Rainbow Child., Dr Agarwal's Hea, Jupiter Life Lin.<BR><BR>Quality Snapshot: Excellent management risk is observed at Max Healthcare, Apollo Hospitals, Narayana Hrudaya, Global Health, Krishna Institu., Rainbow Child., Dr Agarwal's Hea, and Jupiter Life Lin, while Average management risk is found at Fortis Health. and Aster DM Health. Growth is excellent at Max Healthcare and Apollo Hospitals, good at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Jupiter Life Lin, while below average growth is noted at Aster DM Health., Krishna Institu., and Rainbow Child. Capital structure is excellent at Max Healthcare, Global Health, Krishna Institu., and Jupiter Life Lin, average at Apollo Hospitals, and good at Fortis Health., Narayana Hrudaya, Dr Agarwal's Hea, and Rainbow Child., while below average is seen at Aster DM Health.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Krishna Institu. at 85.24%, while the lowest is Dr Agarwal's Hea with no available data. Max Healthcare's 1-year return of 50.36% is significantly higher than Apollo Hospitals' 16.20% but lower than Krishna Institu.'s. Additionally, Aster DM Health. and Dr Agarwal's Hea have negative six-month returns.

View full answer

What does Max Healthcare do?

17-Jul-2025

Max Healthcare Institute Ltd is a large-cap hospital company in India, reporting net sales of ₹19,097 Cr and a net profit of ₹3,190 Cr for March 2025. It has a market capitalization of ₹123,419 Cr and key financial metrics include a P/E ratio of 109.00 and a return on equity of 12.08%.

Overview:<BR>Max Healthcare Institute Ltd operates in the hospital industry and is categorized as a large-cap company.<BR><BR>History:<BR>The company was originally incorporated as "Infinitum Technologies Private Limited" in New Delhi, India, on June 18, 2001. It changed its name to "Max Healthcare Institute Private Limited" following a Fresh Certificate of Incorporation dated June 28, 2002. The latest quarterly results reported are for March 2025.<BR><BR>Financial Snapshot:<BR>Most recent Net Sales: 19,097 Cr (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 3,190 Cr (Quarterly Results - Mar 2025) <BR>Market-cap value: INR 123,419 Cr (Large Cap)<BR><BR>Key Metrics:<BR>P/E: 109.00 <BR>Industry P/E: 59 <BR>Dividend Yield: 0.24% <BR>Debt Equity: 0.25 <BR>Return on Equity: 12.08% <BR>Price to Book: 13.03 <BR><BR>Contact Details:<BR>Address: Not available <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

View full answer

Who are the top shareholders of the Max Healthcare?

17-Jul-2025

The top shareholders of Max Healthcare include Abhay Soi with 23.73%, Foreign Institutional Investors holding 54.74%, and mutual funds with 13.38%. The Government of Singapore is the largest public shareholder at 5.69%, while individual investors own 3.31%, with no pledged promoter holdings.

The top shareholders of Max Healthcare include a mix of institutional and individual investors. The largest shareholder is Abhay Soi, who holds 23.73% of the company. Foreign Institutional Investors (FIIs) are significant shareholders as well, collectively holding 54.74% of the shares, represented by 1020 FIIs. Additionally, mutual funds have a presence with 13.38% held across 33 schemes. The Government of Singapore is the highest public shareholder, owning 5.69%. Individual investors collectively hold 3.31% of the shares. Notably, there are no pledged promoter holdings.

View full answer

How big is Max Healthcare?

24-Jul-2025

As of 24th July, Max Healthcare Institute Ltd has a market capitalization of 122,491.00 Cr, with recent Net Sales of 7028.46 Cr and a Net Profit of 1075.88 Cr. Shareholder's Funds are 9,380.87 Cr, and Total Assets are valued at 15,186.44 Cr.

As of 24th July, Max Healthcare Institute Ltd has a market capitalization of 122,491.00 Cr, categorizing it as a Large Cap company.<BR><BR>For the latest four quarters, the company reported Net Sales of 7028.46 Cr and a Net Profit of 1075.88 Cr.<BR><BR>As of March 2025, the Shareholder's Funds amounted to 9,380.87 Cr, while the Total Assets were valued at 15,186.44 Cr.

View full answer

When is the next results date for Max Healthcare?

07-Aug-2025

The next results date for Max Healthcare is 13 August 2025.

The next results date for Max Healthcare is scheduled for 13 August 2025.

View full answer

Are Max Healthcare latest results good or bad?

13-Aug-2025

Max Healthcare's latest results show strong sales growth and a significant increase in operating profit, but a decline in net profit and cash flow, along with rising debt, indicate underlying challenges that need to be addressed. Overall, the performance is mixed, reflecting both positive trends and concerns.

Max Healthcare's latest results present a mixed picture. On one hand, the company achieved its highest quarterly net sales in the last five quarters, reaching Rs 2,027.57 crore, which indicates a positive trend in sales growth. Additionally, operating profit increased to Rs 522.91 crore, and the profit after tax for the last six months grew by an impressive 28.53%, reflecting strong year-on-year performance.<BR><BR>However, there are notable challenges as well. The company's consolidated net profit saw a decline of 3.46% compared to the previous quarter, which is concerning. Furthermore, operating cash flow has decreased to Rs 598.01 crore, the lowest in three years, suggesting issues with cash revenues from operations. The debt-equity ratio has also risen to 0.32 times, indicating increased borrowing, while cash and cash equivalents have fallen, which could affect short-term liquidity.<BR><BR>In summary, while there are positive aspects such as growth in sales and profitability, the decline in net profit and cash flow, along with increased debt, suggest that the overall performance is somewhat flat and presents challenges that the company needs to address.

View full answer

How has been the historical performance of Max Healthcare?

15-Nov-2025

Max Healthcare has experienced substantial growth from Mar'20 to Mar'25, with net sales increasing from 1,059.03 Cr to 7,028.46 Cr, and profit after tax rising from 12.91 Cr to 1,075.88 Cr. Total assets grew from 3,973.66 Cr to 15,186.44 Cr, reflecting the company's successful expansion strategy.

Answer:<BR>Max Healthcare has shown significant growth in its historical performance, particularly in net sales, which increased from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This upward trend is reflected in total operating income, which also rose from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. The total expenditure, excluding depreciation, grew from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, indicating increased operational costs alongside revenue growth. Operating profit (PBDIT) has similarly improved, climbing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax increased from 12.78 Cr in Mar'20 to 1,406.37 Cr in Mar'25. The profit after tax also saw a rise, reaching 1,075.88 Cr in Mar'25 compared to 12.91 Cr in Mar'20. The company's earnings per share (EPS) increased from 1.1 in Mar'20 to 11.07 in Mar'25, showcasing enhanced profitability per share. On the balance sheet, total assets grew from 3,973.66 Cr in Mar'20 to 15,186.44 Cr in Mar'25, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr in the same period. Cash flow from operating activities improved significantly, reaching 1,459.00 Cr in Mar'25, although cash flow from investing activities showed a negative trend at -1,614.00 Cr.<BR><BR>Breakdown:<BR>Max Healthcare's financial performance has demonstrated remarkable growth over the years, particularly in net sales, which surged from 1,059.03 Cr in Mar'20 to 7,028.46 Cr in Mar'25. This growth in revenue is accompanied by a corresponding increase in total operating income, which reached 7,028.46 Cr in Mar'25, up from 1,059.03 Cr in Mar'20. The company's total expenditure also rose significantly, from 965.45 Cr in Mar'20 to 5,179.66 Cr in Mar'25, reflecting the costs associated with scaling operations. Operating profit (PBDIT) has shown a strong upward trajectory, increasing from 141.66 Cr in Mar'20 to 2,004.44 Cr in Mar'25, while profit before tax improved from 12.78 Cr to 1,406.37 Cr in the same period. The profit after tax reached 1,075.88 Cr in Mar'25, a substantial increase from 12.91 Cr in Mar'20. The earnings per share (EPS) also rose significantly, indicating improved profitability for shareholders. On the balance sheet, total assets expanded from 3,973.66 Cr to 15,186.44 Cr, while total liabilities increased from 3,973.66 Cr to 2,488.83 Cr, reflecting the company's growth strategy. Additionally, cash flow from operating activities improved to 1,459.00 Cr in Mar'25, despite a negative cash flow from investing activities of -1,614.00 Cr, indicating ongoing investments in growth.

View full answer

Should I buy, sell or hold Max Healthcare?

16-Nov-2025

Is Max Healthcare technically bullish or bearish?

05-Dec-2025

As of December 4, 2025, Max Healthcare's trend has shifted to bearish with moderate strength, supported by bearish signals from the MACD, KST, and moving averages, despite some mixed signals on the monthly timeframe.

As of 4 December 2025, the technical trend for Max Healthcare has changed from mildly bearish to bearish. The current stance is bearish with moderate strength. Key indicators driving this include the weekly MACD and KST both showing bearish signals, along with daily moving averages confirming a bearish trend. The Bollinger Bands indicate a bearish outlook on the weekly timeframe, while the monthly indicators show a mix of mildly bearish and mildly bullish signals, suggesting some divergence. Overall, the bearish trend is reinforced by the recent price action, with a notable decline in the past week and month compared to the Sensex.

View full answer

Why is Max Healthcare Institute Ltd falling/rising?

29-Jan-2026

As of 28-Jan, Max Healthcare Institute Ltd's stock price is declining, currently at Rs 957.60, reflecting a 1.82% decrease. The stock has underperformed the sector and broader market, trading below its moving averages and nearing its 52-week low, despite some positive financial indicators.

As of 28-Jan, Max Healthcare Institute Ltd's stock price is falling, currently at Rs 957.60, which reflects a decrease of Rs 17.8 or 1.82%. The stock has been on a downward trend, having lost 4.68% over the past week and 10.88% over the past month. This decline is compounded by the fact that the stock has underperformed the sector by 3.64% today and has been losing for the last four consecutive days.<BR><BR>Additionally, the stock is trading below its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating a bearish trend. The stock is also close to its 52-week low, being only 1.8% away from Rs 940.35.<BR><BR>Despite some positive factors, such as a low debt-to-equity ratio and strong growth in net sales and operating profit, the stock's valuation appears expensive with a return on capital employed (ROCE) of 13.2 and a high enterprise value to capital employed ratio of 7.5. Furthermore, the stock has underperformed the broader market, generating negative returns of -6.51% over the past year while the market has seen returns of 9.89%. This combination of factors contributes to the current decline in Max Healthcare Institute Ltd's stock price.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard

1

With ROCE of 13.2, it has a Very Expensive valuation with a 7.5 Enterprise value to Capital Employed

  • The stock is trading at a premium compared to its peers' average historical valuations
  • Over the past year, while the stock has generated a return of -7.13%, its profits have risen by 33.5% ; the PEG ratio of the company is 2
2

Underperformed the market in the last 1 year

stock-summaryMojo Parameters

Mojo Parameters

Loading Valuation Snapshot...

Stock DNA

stock-summary
Industry

Hospital

stock-summary
Market cap

INR 92,289 Cr (Large Cap)

stock-summary
P/E

66.00

stock-summary
Industry P/E

56

stock-summary
Dividend Yield

0.16%

stock-summary
Debt Equity

0.28

stock-summary
Return on Equity

14.07%

stock-summary
Price to Book

9.27

Revenue and Profits:
Net Sales:
2,135 Cr
(Quarterly Results - Sep 2025)
Net Profit:
491 Cr
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
Dividend Yield (0.16%)
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-20.28%
0%
-20.28%
6 Months
-25.66%
0%
-25.66%
1 Year
-7.39%
0.13%
-7.26%
2 Years
30.88%
0.34%
31.22%
3 Years
108.39%
0.95%
109.34%
4 Years
156.52%
1.09%
157.61%
5 Years
485.31%
2.16%
487.47%

Latest dividend: 1.5 per share ex-dividend date: Jul-04-2025

Risk Adjusted Returns v/s stock-summary
Returns Beta
Icon
Beta has not been calculated since enough price history is not available
stock-summaryNews & Corporate Actions

News

Max Healthcare Institute Ltd Faces Headwinds Amid Nifty 50 Membership and Institutional Shifts

Significance of Nifty 50 Membership

Being part of the Nifty 50 index confers considerable prestige and market attention on Max Healthcare Institute Ltd. As one of the flagship stocks representing the hospital sector within this benchmark, the company benefits from enhanced liquidity, greater institutional interest, and inclusion in numerous index-tracking funds. However, this status also subjects the stock to heightened scrutiny and performance expectations, particularly given the index’s role as a barometer of India’s equity market health.

Max Healthcare’s current market capitalisation stands at a substantial ₹93,175 crores, categorising it firmly as a large-cap stock. Despite this, the company’s recent price action and f...

Read full news article

Max Healthcare Institute Ltd Faces Downward Pressure Amid Nifty 50 Membership and Institutional Shifts

Index Membership and Market Significance

As a constituent of the Nifty 50, Max Healthcare Institute Ltd holds a critical position within India’s benchmark equity index, which represents the top 50 large-cap companies listed on the National Stock Exchange. Inclusion in this index not only underscores the company’s market capitalisation and liquidity but also ensures substantial institutional interest, as many mutual funds, ETFs, and passive investment vehicles track the Nifty 50. Consequently, any shifts in Max Healthcare’s stock performance can have amplified effects on index returns and investor sentiment.

Currently, Max Healthcare’s market capitalisation stands at a robust ₹94,931 crores, categorising it firmly as a larg...

Read full news article

Announcements stock-summary

Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018

06-Jan-2026 | Source : BSE

Certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations 2018

Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS

02-Jan-2026 | Source : BSE

Allotment of Equity Shares under Max Healthcare Institute Limited - Employee Stock Option Scheme 2022

Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015

30-Dec-2025 | Source : BSE

Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Corporate Actions stock-summary

stock-summary
BOARD MEETING

No Upcoming Board Meetings

stock-summary
DIVIDEND

Max Healthcare Institute Ltd has declared 15% dividend, ex-date: 04 Jul 25

stock-summary
SPLITS

No Splits history available

stock-summary
BONUS

No Bonus history available

stock-summary
RIGHTS

No Rights history available

stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
41.05%
EBIT Growth (5y)
312.75%
EBIT to Interest (avg)
10.52
Debt to EBITDA (avg)
1.20
Net Debt to Equity (avg)
0.28
Sales to Capital Employed (avg)
0.54
Tax Ratio
12.89%
Dividend Payout Ratio
13.55%
Pledged Shares
0
Institutional Holding
71.76%
ROCE (avg)
12.27%
ROE (avg)
12.01%

Valuation key factors

Factor
Value
P/E Ratio
66
Industry P/E
56
Price to Book Value
9.27
EV to EBIT
56.50
EV to EBITDA
45.50
EV to Capital Employed
7.48
EV to Sales
12.08
PEG Ratio
1.97
Dividend Yield
0.16%
ROCE (Latest)
13.24%
ROE (Latest)
14.07%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bearish
Mildly Bearish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Bearish
Bearish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

FIIs

Pledged Promoter Holdings

None

Mutual Funds

Held by 40 Schemes (14.04%)

FIIs

Held by 997 FIIs (50.55%)

Promoter with highest holding

Abhay Soi (23.72%)

Highest Public shareholder

New World Fund Inc (4.72%)

Individual Investors Holdings

3.13%

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 5.32% vs 6.17% in Jun 2025",
        "dir": -1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Sep 2025 is 59.53% vs -3.46% in Jun 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Jun'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2,135.47",
          "val2": "2,027.57",
          "chgp": "5.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "575.15",
          "val2": "522.91",
          "chgp": "9.99%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "53.92",
          "val2": "54.85",
          "chgp": "-1.70%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "491.30",
          "val2": "307.97",
          "chgp": "59.53%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "26.93%",
          "val2": "25.79%",
          "chgp": "1.14%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "half-yearly",
    "btn_text": "All Half Yearly Results",
    "header": "Half Yearly Results Snapshot (Consolidated) - Sep'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": " Growth in half year ended Sep 2025 is 28.08% vs 22.74% in Sep 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": " Growth in half year ended Sep 2025 is 54.28% vs 0.26% in Sep 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Sep'25",
        "Sep'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "4,163.04",
          "val2": "3,250.41",
          "chgp": "28.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,098.06",
          "val2": "837.95",
          "chgp": "31.04%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "108.77",
          "val2": "57.42",
          "chgp": "89.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "799.27",
          "val2": "518.08",
          "chgp": "54.28%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "26.38%",
          "val2": "25.78%",
          "chgp": "0.60%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "nine-monthly",
    "btn_text": "All Nine Monthly Results",
    "header": "Nine Monthly Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is 28.51% vs 19.07% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in nine months ended Dec 2024 is -6.11% vs -5.45% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "5,118.72",
          "val2": "3,983.12",
          "chgp": "28.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,337.08",
          "val2": "1,110.59",
          "chgp": "20.39%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "109.81",
          "val2": "39.16",
          "chgp": "180.41%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-73.63",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "756.88",
          "val2": "806.10",
          "chgp": "-6.11%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "26.12%",
          "val2": "27.88%",
          "chgp": "-1.76%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Mar'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Mar 2025 is 30.01% vs 18.49% in Mar 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Mar 2025 is 1.72% vs -4.16% in Mar 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Mar'25",
        "Mar'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "7,028.46",
          "val2": "5,406.02",
          "chgp": "30.01%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "1,848.80",
          "val2": "1,492.12",
          "chgp": "23.90%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "165.02",
          "val2": "59.89",
          "chgp": "175.54%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-73.63",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "1,075.88",
          "val2": "1,057.64",
          "chgp": "1.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "26.30%",
          "val2": "27.60%",
          "chgp": "-1.30%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQstock-summary

Sep'25
Jun'25
Change(%)
Net Sales
2,135.47
2,027.57
5.32%
Operating Profit (PBDIT) excl Other Income
575.15
522.91
9.99%
Interest
53.92
54.85
-1.70%
Exceptional Items
0.00
0.00
Consolidate Net Profit
491.30
307.97
59.53%
Operating Profit Margin (Excl OI)
26.93%
25.79%
1.14%
Values in Rs Cr.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Sep 2025 is 5.32% vs 6.17% in Jun 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Sep 2025 is 59.53% vs -3.46% in Jun 2025

Half Yearly Results Snapshot (Consolidated) - Sep'25stock-summary

Sep'25
Sep'24
Change(%)
Net Sales
4,163.04
3,250.41
28.08%
Operating Profit (PBDIT) excl Other Income
1,098.06
837.95
31.04%
Interest
108.77
57.42
89.43%
Exceptional Items
0.00
0.00
Consolidate Net Profit
799.27
518.08
54.28%
Operating Profit Margin (Excl OI)
26.38%
25.78%
0.60%
Values in Rs Cr.
Direction Arrows
Net Sales

Growth in half year ended Sep 2025 is 28.08% vs 22.74% in Sep 2024

Direction Arrows
Consolidated Net Profit

Growth in half year ended Sep 2025 is 54.28% vs 0.26% in Sep 2024

Nine Monthly Results Snapshot (Consolidated) - Dec'24stock-summary

Dec'24
Dec'23
Change(%)
Net Sales
5,118.72
3,983.12
28.51%
Operating Profit (PBDIT) excl Other Income
1,337.08
1,110.59
20.39%
Interest
109.81
39.16
180.41%
Exceptional Items
-73.63
0.00
Consolidate Net Profit
756.88
806.10
-6.11%
Operating Profit Margin (Excl OI)
26.12%
27.88%
-1.76%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in nine months ended Dec 2024 is 28.51% vs 19.07% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in nine months ended Dec 2024 is -6.11% vs -5.45% in Dec 2023

Annual Results Snapshot (Consolidated) - Mar'25stock-summary

Mar'25
Mar'24
Change(%)
Net Sales
7,028.46
5,406.02
30.01%
Operating Profit (PBDIT) excl Other Income
1,848.80
1,492.12
23.90%
Interest
165.02
59.89
175.54%
Exceptional Items
-73.63
0.00
Consolidate Net Profit
1,075.88
1,057.64
1.72%
Operating Profit Margin (Excl OI)
26.30%
27.60%
-1.30%
Values in Rs Cr.
Direction Arrows
Net Sales

YoY Growth in year ended Mar 2025 is 30.01% vs 18.49% in Mar 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Mar 2025 is 1.72% vs -4.16% in Mar 2024

stock-summaryCompany CV
About Max Healthcare Institute Ltd stock-summary
stock-summary
Max Healthcare Institute Ltd
Large Cap
Hospital
Max Healthcare Institute Limited was originally incorporated as "Infinitum Technologies Private Limited" at New Delhi, India as a Private Limited Company dated June 18 ,2001. Pursuant to a Fresh Certificate of Incorporation dated June 28, 2002, the name of `Infinitum Technologies Private Limited' was changed to `Max Healthcare Institute Private Limited'.
Company Coordinates stock-summary
Icon
No Company Details Available